Duplication of paternal IGF2 or loss of maternal IGF2 imprinting occurs in half of Wilms tumors with various structural WT1 abnormalities
- 7 May 2008
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 47 (8), 712-727
- https://doi.org/10.1002/gcc.20572
Abstract
The WT1 gene essential for the embryonic kidney development is mutated in 15–25% of Wilms tumors (WTs). To clarify whether genetic subtypes of WT1 abnormalities are correlated with IGF2 or CTNNB1 alterations or clinicopathological characteristics, we performed comprehensive WT1, IGF2, and CTNNB1 analyses of 36 WTs with WT1 abnormalities using single nucleotide polymorphism arrays, and methylation analysis of the IGF2‐H19 differentially methylated region. The tumors were classified into three subtypes based on WT1 abnormalities: 13 with WT1 deletion, 12 with WT1 mutation, and 11 with both deletion and mutation. IGF2 alterations were found in 50% (18/36), paternal uniparental disomy (UPD) of 11p13‐11p15 in 13 tumors, UPD limited to 11p15 in 3, and loss of IGF2 imprinting in 2. Quantitative RT‐PCR analysis showed that tumors with IGF2 alteration had higher levels of IGF2 mRNA than tumors without IGF2 alteration (P = 0.02). WT1 mRNA levels were very low in six of eight WTs with WT1 deletion, whereas four of eight WTs with WT1 mutation or both deletion and mutation showed higher levels of WT1 mRNA than fetal kidneys. WTs with WT1 mutations occurred in younger patients (P < 0.01), and WTs with mutations or both deletion and mutation (12/23) were more frequent in syndromic patients than WTs (1/13) with the deletion (P = 0.02). WTs with WT1 mutations or both deletion and mutation had the triphasic histological‐type (15/23; P = 0.03) and CTNNB1 mutation (17/23; P = 0.03) more frequently than WTs with the deletion (2/13 and 4/13). Thus, three WT1 subtypes were correlated with certain genetic and clinicopathological characteristics.Keywords
This publication has 35 references indexed in Scilit:
- A CTCF-binding silencer regulates the imprinted genes AWT1 and WT1-AS and exhibits sequential epigenetic defects during Wilms' tumourigenesisHuman Molecular Genetics, 2007
- Sequential WT1 and CTNNB1 mutations and alterations of -catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studiesJournal of Clinical Pathology, 2006
- Molecular subtypes and phenotypic expression of Beckwith–Wiedemann syndromeEuropean Journal of Human Genetics, 2005
- Insulin‐like growth factor ligands, receptors, and binding proteins in cancerThe Journal of Pathology, 2005
- Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumoursHuman Molecular Genetics, 2003
- Development of an siRNA-based method for repressing specific genes in renal organ culture and its use to show that the Wt1 tumour suppressor is required for nephron differentiationHuman Molecular Genetics, 2003
- Altered expression of members of the IGF-axis in hepatoblastomasBritish Journal of Cancer, 2000
- Repression of the Insulin-Like Growth Factor II Gene by the Wilms Tumor Suppressor WT1Science, 1992
- Treatment of Wilms' tumor. Results of the third national Wilms' tumor studyCancer, 1989
- Histopathology and prognosis of Wilms tumorResults from the first national wilms' tumor studyCancer, 1978